Search Results for “EC” – Page 442 – media

Millions of cancer patients benefit from Elekta’s Flexitron

by John Pinching Brachytherapy is a precise type of radiotherapy that can be used to treat several cancers Elekta has announced that around two million brachytherapy treatments have been delivered by healthcare providers using the company’s Flexitron therapy. Brachytherapy is a very precise type of radiotherapy that can be used to treat a wide variety of cancers. Also known as interventional radiotherapy, it sends a high level of radiation directly onto the tumour, while also minimising exposure to healthy tissue. The treatment has been administered at a high dose rate (HDR) at several locations. One of the most notable sites – Amsterdam University Medical Centers (Amsterdam UMC) – recently contributed to the significant milestone by acquiring the 1,000th Flexitron treatment to be manufactured at Elekta’s production facility in Veenendaal. Indeed, Amsterdam UMC has been providing brachytherapy treatments for more than four decades, using earlier generation brachy afterloaders and Flexitron. The ...
- Source: drugdu
- 135
- April 24, 2023
Kids under 6 were increasingly treated for illicit substance ingestion after Covid-19’s start, study says

The outbreak of Covid-19 presented many dangers for children, and a new study suggests increased illicit substance ingestions were among them. In the first month of the pandemic in 2020, a 25% increase in overall ingestions occurred among children under 6 years old in the United States, according to the study published Friday in JAMA Network Open. Those numbers grew by 1.8% more per month than they did before the pandemic, the study said. “The immediate and sustained increase in opioids ingestions occurred during the largest ever rise in adult overdose deaths, largely driven by synthetic opioids,” said lead study author Dr. Brittany Raffa, a clinical instructor in pediatrics at the University of North Carolina at Chapel Hill and a National Research Service Award primary care research fellow. The study looked at data from 7,659 children under age 6 who were treated for ingestion of amphetamines, benzodiazepines, cannabis, cocaine, ethanol and ...
- Source: drugdu
- 134
- April 24, 2023
Analysis reveals relationship between nutrient consumption and sleep timing

What you eat might influence when you go to sleep, according to a new study of elite female college athletes. Researchers will present their work this week at the American Physiology Summit, the flagship annual meeting of the American Physiological Society (APS), in Long Beach, California.  The study revealed that athletes who consumed more carbohydrates and vitamins B12 and C tended to go to sleep earlier and wake earlier than those who consumed less of these nutrients. According to the researchers, these nutrients might increase synthesis of vital hormones that regulate sleep, including serotonin and melatonin. “For athletes, success is measured not only by readiness to perform but also resiliency on and off the field,” said the study’s first author Lauren Rentz, a doctoral student at West Virginia University. “We know that sleep helps the body heal from daily physical and mental stress and influences future physical and mental ...
- Source: drugdu
- 150
- April 24, 2023
Psychologists map the psyche of extreme altruists

Although many people admire the actions of people who engage in acts of extraordinary altruism, like altruistic organ donors, bone marrow donors, and heroes who rescue people from fires or accidents, they are also often mystified at what motivates these altruists to act. Published in Nature Communications, a new paper from a team of Georgetown researchers aims to answer this question by mapping out the psychological profiles of a range of extreme real-world altruists, like heroic rescuers, humanitarian aid workers, and people who donate organs or bone marrow to strangers at no benefit to themselves. “After evaluating more than 300 extreme altruists, and comparing them to a baseline cohort of typical adults, we found that exceedingly generous people are best distinguished from typical adults by their unselfish traits and preferences,” said Abigail Marsh, the paper’s senior author. “But they are not different in a lot of other ways. They are not ...
- Source: drugdu
- 131
- April 20, 2023
ICR in research partnership with NeoPhore

Collaboration will further boost its promising pipeline of cancer treating therapies NeoPhore – a company focused on small molecule neoantigen immuno-oncology – has announced that it is collaborating with Professor Chris Lord’s lab at The Institute of Cancer Research (ICR) in London. Under the terms of the agreement, the lab will use NeoPhore’s proprietary small molecule inhibitors of DNA mismatch repair (MMR) to explore single agent activity amid tumours with defined genetic backgrounds. Meanwhile, its promising MMR modulators have the ability to induce neoantigen expression and increase immunogenicity in solid tumours that become sensitive to immunotherapy. The collaboration will further develop NeoPhore’s discoveries and ongoing research, while boosting its pipeline of cancer treating therapies. It also becomes the fourth partnership established by NeoPhore during the past six years, having also made reached agreements with St George’s University of London, Memorial Sloan Kettering Cancer Center and ...
- Source: drugdu
- 116
- April 20, 2023
GSK to buy Bellus Health and its chronic cough drug for $2B

GSK on Tuesday said it will pay $2 billion to acquire Bellus Health, a Canada-based developer of an experimental drug for chronic cough that’s in late-stage clinical trials. Deal terms value each Bellus share at $14.75, roughly double their closing price on Monday. The companies expect the acquisition will close in the third quarter, and Bellus’ board has unanimously voted in its favor. Bellus’ drug, called camlipixant, is currently being tested in two Phase 3 studies of people with persistent cough that either doesn’t have a clear cause or can’t be relieved by treatment for an underlying condition. Results are expected in late 2024 and in 2025, respectively. With the Bellus deal, GSK will gain a drug that could compete with a similar treatment being developed by Merck & Co. Both medicines are designed to work by targeting a receptor known as P2X3, and could become the first ...
- Source: drugdu
- 335
- April 20, 2023
J&J study data show dramatic benefit to multiple myeloma cell therapy

A study abstract inadvertently posted online showed J&J and Legend’s therapy, Carvykti, reduced the risk of disease progression or death by more than 70% over standard drugs. The cancer cell therapy Carvykti dramatically outperformed standard drugs in a late-stage clinical trial testing its use in earlier treatment of the blood cancer multiple myeloma, according to data from a study abstract that was briefly posted online Tuesday. The abstract showed Carvykti, which is made by Johnson & Johnson and Legend Biotech, reduced the risk of disease progression or death by 74% compared to standard of care — a degree of benefit that analysts who viewed it described as “stellar” and “highly encouraging.” J&J and Legend had previously said in late January that the study met its main goal, but did not disclose any specific data at the time. The abstract, which is no longer available online, was for presentation ...
- Source: drugdu
- 109
- April 20, 2023
Ardelyx resubmits NDA for Xphozah to US FDA

Ardelyx has resubmitted a new drug application (NDA) for Xphozah (tenapanor) to the US Food and Drug Administration (FDA). A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response or intolerance to a phosphate binder therapy. It has a new action mechanism and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). This reduces the absorption of phosphate via the paracellular pathway, which is the main pathway of phosphate absorption. Diarrhea was the most common side effect using Xphozah in clinical trials. The NDA submission was supported by a comprehensive development programme, which included over 1,200 patients in three Phase III clinical trials, PHREEDOM, BLOCK and AMPLIFY, and two additional open-label Phase IV clinical trials, OPTIMIZE and NORMALIZE. The Phase III trials were ...
- Source: drugdu
- 133
- April 20, 2023
Is there a link between psychiatric and reproductive system disorders in women?

In a recent study published in the journal JAMA Network Open, researchers performed a meta-analysis to assess the co-occurrence of reproductive and psychiatric disorders among women. Disorders associated with the female mental well-being and reproductive tract commonly co-exist; however, the precise cause of the co-occurrence is not clear. Probable causes include non-intrinsic or external-type factors that interfere with the reproductive system, including psychotropic-type medications, psychosocial causes like reproductive disorders impacting relationships and life quality, and stress affecting reproductive functions and the menstrual cycle. Moreover, the overlap could originate from genetic causes. About the study In the present meta-analysis, researchers determined the association between female reproductive and psychiatric functions. The PubMed database was searched for observational-type and peer-reviewed studies (population-level cross-sectional and case-control studies), including reproductive-age females aged between 13.0 and 55.0 years, published from January 1980 to December 2019, evaluating the prevalence of mental health disorders among ...
- Source: drugdu
- 108
- April 20, 2023
CDC signs off on additional Covid-19 booster doses for certain people

The US Centers for Disease Control and Prevention updated its recommendations on the Covid-19 vaccines on Wednesday to allow another dose of the bivalent booster for people who are 65 and older or who have weakened immune systems and who “want the option of added protection” against the coronavirus. The move aligns with Tuesday’s US Food and Drug Administration actions to allow these groups to get additional booster doses ahead of the fall vaccination campaign. On Wednesday, members of CDC’s Advisory Committee for Immunization Practices met to discuss the changes and expressed their support for them, although the committee did not vote. Monovalent mRNA vaccines, which protect only against the original strain of the coronavirus, will no longer be recommended in the United States, the CDC says. The updated bivalent shots from Moderna and Pfizer/BioNTech protect against the original strain as well as the BA.4 and BA.5 subvariants ...
- Source: drugdu
- 103
- April 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.